$GKOS

Thurman Alex R. sold $1.6M of GKOS

Thurman Alex R. (SVP & CHIEF FINANCIAL OFFICER) sold 10,000 shares of GLAUKOS Corp (GKOS) at $155.00 ($1.55M total) on 2026-07-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thurman Alex R.
Published Jul 14, 2026, 12:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 14, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GKOS
Neutral
high confidence
Mentioned
$GKOS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The newest concrete fact is the CFO’s open-market sale of 10,000 shares at $155/share, totaling $1.55M, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment, but there is no new fundamental catalyst in the filing.

03

What to watch

Insider sales can be scheduled regardless of company outlook; without accompanying buys or new company disclosures, the trading signal is weak.

Relevance 5/10Novelty 3/10Timing: New SEC Form 4 filed 2026-07-13, covering a sale dated 2026-07-09.

Background

The article is an SEC Form 4 insider transaction disclosure for Glaukos Corp, identifying the CFO and the sale details.

Company-level read

Ticker impact

$GKOSNeutralHigh confidence
Context

Glaukos CFO Thurman Alex sold 10,000 shares on 2026-07-09 at $155/share under a pre-arranged 10b5-1 plan, per Form 4.

Expected impact

Likely minimal near-term price impact; any reaction is more sentiment-driven than fundamental.

Evidence & confidence

The filing is an insider transaction (not a guidance, contract, or regulatory event). The presence of a pre-arranged 10b5-1 plan typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider activity without operational or regulatory details.

None indicated.

None indicated.

Counterpoint

The sale could be purely liquidity-driven and not a bearish signal, especially given the stated 10b5-1 plan.

Key entities

  • GLAUKOS Corp

    Company whose CFO filed the insider sale on Form 4.

  • Thurman Alex R.

    SVP and Chief Financial Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GKOSMed

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal

Glaukos Corporation (GKOS) licensed RO-104, a tri-specific biologic for retinal diseases, from RevOpsis Therapeutics. The deal grants GKOS exclusive rights to RevOpsis' RevMod platform for up to four additional candidates. GKOS stock fell 6.3% post-announcement but is up 42.8% year-to-date. The agreement aims to expand GKOS' retinal therapeutics pipeline and market presence.

$GKOSMed

Glaukos Corp (GKOS) Reports Positive Phase 4 Trial Results for i

Glaukos Corp (GKOS) reported positive phase 4 trial results for its iDose TR implant, showing significant reduction in intraocular pressure. The company trades at a P/S ratio of 15.24, above historical and industry medians, reflecting growth expectations. It has a GF Score of 79, indicating strong growth and financial health despite unprofitability. Insiders sold $67.8M in shares over the past year, while institutional investors increased holdings.

$GKOSMed

Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy - Glaukos (NYSE:GKOS)

Glaukos (NYSE:GKOS) reported positive Phase 4 trial results for its iDose TR therapy combined with cataract surgery. The treatment reduced intraocular pressure by 11.1 mmHg vs. 7.4 mmHg for surgery alone, meeting primary efficacy goals. The study showed no serious safety issues. The therapy aims to improve patient compliance with long-lasting drug delivery. GKOS shares are up 0.12% at $161.49.

$GKOSMedAI 9/10

Glaukos Reports Positive Phase 4 Results for iDose TR

Glaukos Corp. reported positive Phase 4 results for its iDose TR glaucoma treatment, meeting the primary endpoint and showing superiority in reducing intraocular pressure. The company also secured an exclusive licensing agreement with RevOpsis Therapeutics for retinal disease treatments. Shares of Glaukos (GKOS) were trading at $161.16 with a $9.5 billion market cap.